Overview

Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients

Status:
Active, not recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
A study to evaluate changes over time in renal function from baseline (time of conversion) up until five years post conversion in kidney transplant patients converted from tacrolimus twice daily (BD) formulations to a once daily formulation as Advagraf.
Details
Lead Sponsor:
Astellas Pharma Europe Ltd.
Treatments:
Tacrolimus